12400 High Bluff Drive
121 articles with Evofem Biosciences
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM).
The conference will be held at the InterContinental New York Barclay Hotel in New York, NY.
Management to Host Conference Call at 11:00 a.m. EDT
Evofem Biosciences, Inc., will hold a conference call to discuss financial results and business highlights for the first quarter ended March 31, 2019
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
Evofem Biosciences, Inc. announced the completion of patient enrollment in AMPREVENCE, the Phase 2b clinical trial evaluating its lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator™, for the prevention of chlamydia and gonorrhea in women.
Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand female contraceptive
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc.
Evofem's management team will host one-on-one meetings with investors during the conference.
Evofem Biosciences, Inc.,, a clinical-stage biopharmaceutical company, announced it will present at the following investor conferences on Tuesday March 19, 2019
Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Evofem Biosciences, Inc.,, a clinical stage biopharmaceutical company, reported financial results for the three- and twelve- month periods ended December 31, 2018.
Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
Evofem Biosciences, Inc., will hold a conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2018
- Company to Resubmit New Drug Application (NDA) for Amphora as Hormone-free Birth Control in Q2 2019 Based on Positive Top-line Phase 3 Study Results -
Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed
Evofem Biosciences, Inc. announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference, as follows:
Company Remains on Track for AMPOWER Top-line Results in Late 2018
Management to Host Conference Call at 11:00 a.m. EST
Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced it will host a key opinion leader event in New York City on Thursday, November 15, 2018
Conference Call Scheduled for 11:00 a.m. EST
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced details of two oral presentations of data related to their lead product, Amphora®
Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress
Evofem Biosciences, Inc. will present an update on the methodology and status of two ongoing late stage clinical trials of its lead product candidate, Amphora®.